Sanofi-Aventis U.S. agreed to pay $11.85 million to resolve allegations that it violated the False Claims Act by paying kickbacks to Medicare patients prescribed the multiple sclerosis drug Lemtrada through a purportedly independent charitable foundation, The Assistance Fund (TAF). Sanofi also entered into a corporate integrity agreement with the Department of Health and Human Services Office of Inspector General. The government alleged that Sanofi made payments to TAF in 2015 and 2016 not with a charitable purpose but rather with the intention of using TAF as a conduit to pay the financial obligations, including Medicare co-pay obligations, of patients taking Lemtrada, and that those payments violated the Anti-Kickback Statute.